Dermatology

Topical ruxolitinib shows sustained repigmentation over years, while oral JAK inhibitors move toward approval for widespread disease, George Martin, MD, says.

This Q&A interview highlights Katta's views on dietary and nutritional supplements' impact on skin health as well as their long-term effects.

This review highlights some of the most notable stories covered by the HCPLive team within the first half of 2026.

At Maui Derm Summer 2026, Hilary Baldwin, MD, used a single theoretical patient to illustrate how rosacea subtypes evolve and how treatment should follow suit.

At Maui Derm NP+PA Summer 2026, Benjamin Ungar, MD, detailed how JAK inhibitors and oral minoxidil are reshaping hair loss treatment strategy.

This review highlights the most notable dermatology news stories covered by HCPLive during the second quarter of 2026.

Frieden discusses somatic mutations driving vascular malformations and how repurposed cancer therapies like alpelisib and sirolimus are changing care.

Rajani Katta, MD, an author and dermatologist, spoke regarding her SDPA session on diet and its connection to dermatology.

This interview highlights both key findings and the significance of the POSITIVE trial for clinicians and for individuals with psoriasis.

This review of June 2026 headlines covers the most notable stories in dermatology, including FDA news, new data, and podcast updates.

This interview segment from SDPA highlights insights on hormonal impacts on dermatology as well as other key highlights from sessions at the meeting.

A review of 9 novel drugs approved by the US Food and Drug Administration during the second quarter of 2026.

This interview at the SDPA Summer Conference highlights key myths and how to address them as a clinician in dermatology.

A review of 22 novel drugs approved by the US Food and Drug Administration during the first half of 2026, with links to coverage from MJH Life Sciences publications.

New AD biologic data highlight early systemic treatment, durable itch control, and improved pediatric growth—shifting goals beyond skin clearance.

Frieden shares practical tips on repurposing topical timolol and sirolimus for pediatric skin conditions.

Rajani Katta, MD, on navigating the diet-skin connection: evidence, myths, and clinical ownership.

FDA approves steroid-free roflumilast cream for plaque psoriasis in children age 2+, bringing once-daily option for sensitive areas.

Frieden on expanding dupilumab use in pediatric skin conditions: prurigo nodularis, EB pruriginosa, and more.

At Maui Derm NP+PA Summer 2026, Matthew Zirwas, MD, shares cases of a factory worker with PPD allergy and a chronic spontaneous urticaria patient with persistent facial dermatitis.

Matthew Zirwas, MD, on why adult-onset atopic dermatitis is the most undertreated condition in dermatology and how diagnostic criteria are driving years of delayed care.

Dawn Eichenfield, MD, discusses off-label treatment rationale, biologics, JAK inhibitors, and care gaps in rare pediatric skin conditions.

Donna Culton, MD, PhD, explains why autoimmune blistering diseases often look nothing like the textbook and how to pursue the diagnosis anyway.

Stefan Weiss, MD, on recognizing mast cell disorders in the dermatology clinic and how avapritinib is reshaping treatment for indolent systemic mastocytosis.

The topic of precision medicine in dermatology is explored in this segment of Bunick's interview at RAD 2026.